NASDAQ · VRTX

Vertex Pharmaceuticals Inc.

$479.00 +$1.64 (+0.34%) 1D After hours
Charting by TradingView

Key Metrics

$121.16B
Market cap
27.93×
P/E · TTM
$12.22B
Revenue · TTM
$4.34B
Net income
EPS · TTM $16.72
Dividend yield —
Free cash flow $3.71B
Beta · 1Y 0.59
EBITDA · TTM $5.38B
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 10
    The stock moved +8.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 10

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$121.16B
Enterprise value—
Shares outstanding253.8M
52-wk range$362.50 – $533.67
Avg volume · 20D1.5M
Net cash —
Book value / share$74.61
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Vertex Pharmaceuticals Inc.
IPO dateJul 31, 1991
Employees6400

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E27.93
P/S9.92
P/FCF32.65
EV/EBITDA—
EV/Sales—
Graham №$167.53

Profitability

Gross —
Operating 42.3%
Net 35.5%
FCF 30.4%
ROE / ROIC 24.3% · 35.8%

Financial Health

Current ratio3.02
Quick ratio2.57
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital$7.85B

Cash Flow · TTM

Operating CF $4.24B
Capex −$530.30M
Free cash flow $3.71B
Buybacks $1.93B
Dividends paid —
Shareholder yield 1.6%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

12.4
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$167.53 vs $479.00
Trades 2.9× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings